Vascular Brain Damage in Thalassemia Syndrome: An Emerging Challenge Stroke in Thalassemia Syndrome
Iranian Journal of Child Neurology,
Vol. 16 No. 1 (2022),
1 January 2022
,
Page 19-29
https://doi.org/10.22037/ijcn.v16i3.33794
Abstract
Abstract
Thalassemia syndromes are the most prevalent monogenic hemoglobinopathy in the world. In Iran, thalassemia is a public health problem because this country has been located on the thalassemia belt. In recent decades, considering that the life expectancy of patients with thalassemia has dramatically improved, some unrecognized complications have emerged in these individuals. One of these complications is a hypercoagulable state that may lead to thromboembolic events (TEE). The TEE may involve any organ in the body, including the central nervous system. Ischemic cerebrovascular events in thalassemic patients have been divided into two categories, namely overt stroke and silent cerebral infarcts (SCI). Overt stroke often develops in patients with beta-thalassemia major; however, patients with thalassemia intermedia usually suffer from SCI. This review article discusses brain vascular involvement.
- Thalassemia, Hypercoagulable state, Thrombosis, Stroke, Infarct
How to Cite
References
References
-Borgna-Pignatti C, Gamberini MR. Complications of thalassemia major and their treatment. Expert Rev Hematol. 2011;4(3):353-66. doi: 10.1586/ehm.11.29. PubMed PMID: 21668399.
- Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, et al. Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol. 2007 Apr;29(4):233-8. doi: 10.1097/MPH.0b013e3180437e02. PMID: 17414565.
-Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassemia
patients: current strategies and future directions. J Blood Med. 2015; 6:197-209. doi: 10.2147/JBM. S72463. PubMed PMID: 26124688. PubMed Central PMCID: PMC4476479.
- Papakonstantinou O, Alexopoulou E, Economopoulos N, Benekos O, Kattamis A, Kostaridou S, et al. Assessment of iron distribution between liver, spleen,pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with beta thalassemia major. J Magn Reson Imaging. 2009;29(4):853-9. doi: 10.1002/jmri.21707. PubMed PMID:19306409.
-Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002 Jan 1;99(1):36-43. doi: 10.1182/blood. v99.1.36. PMID: 11756150.
-Cappellini MD, Motta I, Musallam KM, Taher AT. Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci. 2010 Aug; 1202:231-6. doi: 10.1111/j.1749-6632.2010.05548. x. PMID: 20712798.
- Musallam KM, Taher AT. Thrombosis in thalassemia: why are we so concerned? Hemoglobin. 2011;35(5-6):503-10. doi: 10.3109/03630269.2011.605499. Epub 2011 Sep 12. PMID: 21910599.
-Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol. 2007 Oct;139(1):3-13. doi: 10.1111/j.1365-2141.2007.06740. x. PMID: 17854302.
- Cappellini MD, Poggiali E, Taher AT, Musallam KM. Hypercoagulability in β-thalassemia: a status quo. Expert Rev Hematol. 2012 Oct;5(5):505-11; quiz 512. doi: 10.1586/ehm.12.42. PMID: 23146054.
-Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000 Nov;111(2):467-73. doi: 10.1046/j.1365-2141.2000.02376. x. PMID: 11122086.
-Taher A, Abou-Mourad Y, Abchee A, Zalouaa P, Shamseddine A. Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication? Hemoglobin. 2002 May;26(2):107-12. doi: 10.1081/hem-120005447. PMID: 12144052.
-Zafeiriou DI, Economou M, Athanasiou-Metaxa M. Neurological complications in beta-thalassemia. Brain Dev. 2006 Sep;28(8):477-81. doi: 10.1016/j.braindev.2006.02.005. Epub 2006 Mar 29. PMID: 16574362.
- Cappellini MD, Motta I, Musallam KM, Taher AT. Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci. 2010 Aug; 1202:231-6. doi: 10.1111/j.1749-6632.2010.05548.x. PMID:20712798
-Taher A, Isma'eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006 Oct;96(4):488-91. PMID: 17003927.
-Sleiman J, Tarhini A, Bou-Fakhredin R, Saliba AN, Cappellini MD, Taher AT. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. Int J Mol Sci. 2018 Jan 8;19(1):182. doi: 10.3390/ijms19010182. PMID: 29316681; PMCID: PMC5796131.
-Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost. 2010 Oct;8(10):2152-8. doi: 10.1111/j.1538-7836.2010.03940. x. PMID: 20546125.
-Taher AT, Cappellini MD, Bou-Fakhredin R, Coriu D, Musallam KM. Hypercoagulability and Vascular Disease. Hematol Oncol Clin North Am. 2018 Apr;32(2):237-245. doi: 10.1016/j.hoc.2017.11.001. Epub 2017 Dec 1. PMID: 29458729.
-Cappellini MD, Motta I, Musallam KM, Taher AT. Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci. 2010 Aug; 1202:231-6. doi: 10.1111/j.1749-6632.2010.05548. x. PMID: 20712798.
- Hassan TH, Elbehedy RM, Youssef DM, Amr GE.Protein C levels in beta-TMpatients in the east Nile delta of Egypt. Hematol Oncol Stem Cell Ther. 2010;3(2):60-5. PMID:20543538
- Tripatara A, Jetsrisuparb A, Teeratakulpisarn J, Kuaha K. Hemostatic alterations in splenectomized and non-splenectomized patients with beta-thalassemia/hemoglobin E disease. Thromb Res. 2007;120(6):805- 10. doi.org/10.1016/j.thromres.2007.02.006.PMID:17382994
- Sipahi T, Kara A, Kuybulu A, Egin Y, Akar N. Congenital thrombotic risk factors in beta thalassemia. Clin Appl Thromb Hemost. 2009 Oct;15(5):581-4. doi:10.1177/1076029608316170. PMID:18480081
-Abosdera MM, Almasry AE, Abdel-Moneim ES. Coagulation defects in thalassemic patients. Pediatr Neonatol. 2017 Oct;58(5):421-424. doi: 10.1016/j.pedneo.2016.07.009. PMID:28351558
-Succar J, Musallam KM, Taher AT. Thalassemia and venous thromboembolism. Mediterr J Hematol Infect Dis. 2011;3(1): e2011025. doi: 10.4084/ MJHID.2011. 025.PMID:21713079
-Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010 Mar 11;115(10):1886-92. doi: 10.1182/blood-2009-09-243154. PMID: 20032507.
-Nemtsas P, Arnaoutoglou M, Perifanis V, Koutsouraki E, Orologas A. Neurological complications of beta-thalassemia. Ann Hematol. 2015 Aug;94(8):1261-5. doi: 10.1007/s00277-015-2378-z. Epub 2015 Apr 24. PMID: 25903043.
-Haghpanah S, Karimi M. Cerebral thrombosis in patients with β-thalassemia: a systematic review. Blood Coagul Fibrinolysis. 2012 Apr;23(3):212-7. doi: 10.1097/MBC.0b013e3283502975. PMID: 22322139.
-Taher AT, Musallam KM, Nasreddine W, Hourani R, Inati A, Beydoun A. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost. 2010 Jan;8(1):54-9. doi: 10.1111/j.1538-7836.2009.03651. x. Epub 2009 Oct 11. PMID: 19817994.
- Kanavaki A, Spengos K, Moraki M, Delaporta P, Kariyannis C, Papassotiriou I, et al. Serum Levels of S100b and NSE Proteins in Patients with Non-Transfusion-Dependent Thalassemia as Biomarkers of Brain Ischemia and Cerebral Vasculopathy. Int J Mol Sci. 2017 Dec 15;18(12):2724. doi: 10.3390/ijms18122724. PMID: 29244749; PMCID: PMC5751325.
-Musallam KM, Beydoun A, Hourani R, Nasreddine W, Raad R, Koussa S, et al. Brain magnetic resonance angiography in splenectomized adults with β-thalassemia intermedia. Eur J Haematol. 2011 Dec;87(6):539-46. doi: 10.1111/j.1600-0609.2011.01706. x. PMID: 21913989.
-Karimi M, Haghpanah S, Bagheri MH, Bordbar MR, Pishdad P, Rachmilewitz EA. Frequency and distribution of asymptomatic brain lesions in patients with β-thalassemia intermedia. Ann Hematol. 2012 Dec;91(12):1833-8. doi: 10.1007/s00277-012-1527-x. Epub 2012 Jul 24. PMID: 22824997.
-Karimi M, Bagheri H, Rastgu F, Rachmilewitz EA. Magnetic resonance imaging to determine the incidence of brain ischaemia in patients with beta-thalassaemia intermedia. Thromb Haemost. 2010 May;103(5):989-93. doi: 10.1160/TH09-09-0661. Epub 2010 Feb 19. PMID: 20174764.
- Masood SA, Zaidi A. Post-transfusion hypertension, convulsion and intracranial haemorrhage in β-thalassemia major. J Coll Physicians Surg Pak. 2012 Jul;22(7):473-5. PMID: 22747874.
- Musallam KM, Nasreddine W, Beydoun A, Hourani R, Hankir A, Koussa S, et al. Brain positron emission tomography in splenectomized adults with β-thalassemia intermedia: uncovering yet another covert abnormality. Ann Hematol. 2012 Feb;91(2):235-41. doi: 10.1007/s00277-011-1291-3. Epub 2011 Jul 13. PMID: 21750926.
- Pazgal I, Inbar E, Cohen M, Shpilberg O, Raanani P, Rachmilewitz E, et al. C0431: High incidence of thrombotic cerebral lesions in adult patients with beta-thalassemia major. Thrombosis Research. 2014 May 1;133: S116.
- Musallam KM, Taher AT, Karimi M, Rachmilewitz EA. Cerebral infarction in β-thalassemia intermedia: breaking the silence. Thromb Res. 2012 Nov;130(5):695-702. doi: 10.1016/j.thromres.2012.07.013. Epub 2012 Aug 3. PMID: 22857801.
- Auer JW, Berent R, Weber T, Eber B. Iron metabolism and development of atherosclerosis. Circulation. 2002 Jul 9;106(2): e7; author reply e7. doi: 10.1161/01.cir.0000019984.69119.4f. PMID: 12105175.
- Vassilopoulou S, Paraskevas GP, Anagnostou E, Papadimas GK, Spengos K. Cerebral venous sinus thrombosis in an adult with sickle β°-thalassemia. Eur J Neurol. 2011 May;18(5): e51. doi: 10.1111/j.1468-1331.2010.03289. x. Epub 2010 Dec 15. PMID: 21159071.
- Teli A, Economou M, Rudolf J, Tzovaras F, Gourtsa V, Kondou A, et al. Subclinical central nervous system involvement and thrombophilic status in young thalassemia intermedia patients of Greek origin. Blood Coagul Fibrinolysis. 2012 Apr;23(3):195-202. doi: 10.1097/MBC.0b013e32834f0ac0. PMID: 22322135.
- Ashjazadeh N, Emami S, Petramfar P, Yaghoubi E, Karimi M. Intracranial Blood Flow Velocity in Patients with β-Thalassemia Intermedia Using Transcranial Doppler Sonography: A Case-Control Study. Anemia. 2012; 2012:798296. doi: 10.1155/2012/798296. Epub 2011 Dec 29. PMID: 22263107; PMCID: PMC3254003.
- Bloomfield SM, McKinney J, Smith L, Brisman J. Reliability of S100B in predicting severity of central nervous system injury. Neurocrit Care. 2007;6(2):121-38. doi: 10.1007/s12028-007-0008-x. PMID: 17522796.
- Karimi M, Haghpanah S, Pishdad P, Zahedi Z, Parand S, Safaei S. Frequency of silent brain lesions and aspirin protection evaluation over 3 years’ follow-up in beta thalassemia patients. Ann Hematol. 2019 Oct;98(10):2267-2271. doi: 10.1007/s00277-019-03765-0. Epub 2019 Aug 6. PMID: 31388698.
- Sirachainan N, Wijarn P, Chuansumrit A, Kadegasem P, Wongwerawattanakoon P, oisamrong A.Aspirin resistance in children and young adults with splenectomized thalassemia diseases. Thromb Res. 2 015 M ay;135(5):916-22. d oi: 1 0.1016/j. thromres.2015.03.003. PMID:25776469
- Asadov C, Alimirzoeva Z, Mammadova T, Aliyeva G, Gafarova S, Mammadov J. β-Thalassemia intermedia: a comprehensive overview and novel approaches. Int J Hematol. 2018 Jul;108(1):5-21. doi: 10.1007/s12185- 018-2411-9. PMID: 29380178
- Karim M, Cohan N, De Sanctis V, Mallat NS, Taher A. Guidelines for diagnosis and management of Beta thalassemia intermedia. Pediatr Hematol Oncol. 2014 Oct;31(7):583-96. doi: 10.3109/08880018.2014.937884. PMID:25247665
- Monaco L, Biagi C, Conti V, Melis M, Donati M, Venegoni M, et al. Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Br J Clin Pharmacol. 2017 Jul;83(7):1532-1543. doi: 10.1111/bcp.13234. Epub 2017 Mar 19. PMID: 28071818; PMCID: PMC5465343.
- Hicks T, Stewart F, Eisinga A. NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. Open Heart. 2016 Jan 18;3(1): e000279. doi: 10.1136/openhrt-2015-000279. PMID: 26848392; PMCID: PMC4731839.
- Apostolou C, Klonizakis P, Mainou M, Kapsali E, Kafantari K, Kotsiafti A, et al. Rivaroxaban Use in Patients with Hemoglobinopathies. Hemoglobin. 2017 May;41(3):223-224. doi: 10.1080/03630269.2017.1374969. PMID: 28950780.
-Cordeanu M, Gaertner S, Bensalah N, Mirea C, Hamade A, Stephan D. Rivaroxaban induced liver injury: A cholestatic pattern. Int J Cardiol. 2016 Aug 1; 216:97-8. doi: 10.1016/j.ijcard.2016.04.063. Epub 2016 Apr 13. PMID: 27140342.
- Abstract Viewed: 519 times